Breaking Finance News

RBC Capital covered Regeneron Pharma (NASDAQ:REGN), upping its target price to $475.00 today

Regeneron Pharma (NASDAQ:REGN) had its target price raised to $475.00 by RBC Capital in a report released 09/15/2017. The new target price indicates a possible upside of 0.08% based on the company's last closing price.

Previously on 8/17/2017, Evercore ISI reported on Regeneron Pharma (NASDAQ:REGN) raised the target price from $0.00 to $605.00. At the time, this indicated a possible upside of 0.29%.

Yesterday Regeneron Pharma (NASDAQ:REGN) traded -0.70% lower at $441.30. The company’s 50-day moving average is $474.95 and its 200-day moving average is $444.94. The last closing price is down -1.52% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 318,067 shares of the stock were exchanged, down from an average trading volume of 859,475

See Chart Below

Regeneron Pharma (NASDAQ:REGN)

Regeneron Pharma has a 52 week low of $325.35 and a 52 week high of $543.55 with a P/E ratio of 43.96 The company’s market cap is currently $0.

In addition to RBC Capital reporting its target price, a total of 21 brokers have issued a report on Regeneron Pharma. The 12-month price target is $475.76 with eight analysts rating the company a strong buy, six equity analysts rating the company a buy, eleven equity analysts rating the company a hold, one firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Regeneron Pharma (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *